Answers are grounded in this paper and cite their sources.
Long-read genotyping reveals mutations in HSPCs drive disease progression in myeloproliferative neoplasms, highlighting new insights into acute myeloid leukemia.
Myeloproliferative neoplasms (MPNs) are caused by acquired mutations in hematopoietic stem and progenitor cells (HSPCs). The acquisition of additional mutations like TP53 and the overall mutational burden influence a patient's risk of disease progression toward lethal post-MPN acute myeloid leukemia (AML). Recent technological advancements in linking single-cell gene expression with genotype have improved our understanding of tumor heterogeneity. However, current methodologies have limitations in simultaneously genotyping low-expression genes (such as JAK2 ) alongside other pathogenic loci. To address this, we developed a novel long read genotyping of transcriptomes pipeline called LOTR-Seq, which can genotype the full length of 30 expressed genes at once. Using LOTR-Seq, we genotyped HSPCs at the JAK2V617F locus in 9,075 single cells from eight patients with chronic phase MPN (CP-MPN) and in 5,016 cells from four patients with post-MPN AML. We then linked the mutations to the single cell transcriptome of 29,712 JAK2V617F -driven CP-MPN cells and 16,895 post-MPN AML cells. In our analysis of post-MPN AMLs, we identified nine mutated loci across six genes ( JAK2, IDH1/2, TP53, SRSF2, U2AF1 ) and linked these mutations to specific transcriptional phenotypes. Overall, LOTR-Seq has provided us with unparalleled insights into the pathogenesis of the JAK2V617F mutation in HSPCs in CP-MPN and the effects of secondary mutations in post-MPN AML.
No takes yet. Share an insight, caveat, or question.
Grabek et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: